Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
| 対象疾患 | Glioblastoma |
|---|---|
| 相 | 第2相 |
| スポンサー | University of Pennsylvania |
| ステータス | 実施中（募集終了） |
| 参加者数 | 39 名 |
| 介入（薬剤） | INCMGA00012, INCAGN01876, SRS, Brain surgery |
| 開始日 | 2020年6月23日 |
| 完了日 | 2022年9月8日 |
| 結果公開日 | 2023年9月15日 |
概要
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
Objective Radiographic Response (ORR)
| GITR + PD1, SRS (Cohort A) | 0 % of participants with response |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen